No Detail Found!

Anti-Mullerian hormone and associated pregnancy outcomes in females with polycystic ovary syndrome undergoing in vitro fertilization-embryo transfer

Author(s)
Jiacheng Du Second People’s Hospital of Jingmen City, Jingmen City, China.
Yuping Cao Second People’s Hospital of Jingmen City, Jingmen City, China.
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged women worldwide. Pregnancy in these women is highly aefcted by serum levels of Anti-Mullerian hormone (AMH). This study aimed to determine the association of serum AMH levels with pregnancy outcomes in females with PCOS undergoing in vitro fertilization-embryo transfer (IVF-ET) Methods: A total of 200 PCOS patients undergoing IVF-ET in the Reproductive Medicine Center, Second People's Hospital of Jingmen, China were included. The patients were divided into two groups, A and B, based on their AMH levels. Serum sex hormones levels and pregnancy outcomes in terms of fertilization, cleavage, implantation, high quality embryo, and biochemical and clinical pregnancy rates were compared. Results: Mean age of the patients was 28.74 ± 2.07 years in group A and 29.74 ± 2.23 years in group B. Participants in group A had lower serum levels of follicle stimulating hormone, luteinizing hormone, and testosterone compared to group B. Also, beetr pregnancy outcomes and lower frequency of pregnancy complications were seen in the participants of group A (p < 0.05). AMH serum levels showed high specificity and sensitivity in predicting IVF-ET clinical pregnancy in PCOS patients. Conclusion: Serum AMH levels in females with PCOS predict improved sex hormones profile and clinical pregnancy outcomes aeftr IVF-ET
Publication Details
Page(s) 240-247
Published Journal: Biomedica, Volume: 37, Issue: 4, Year: 2021

Request the full text from PASTIC

Keywords
Anti-mullerian hormone, Outcome, Polycystic ovary syndrome
References
Kumari R,Kanika J,Debasis D .2018 .Comparison of clinical outcomes in clomiphene citrate resistant infertile polycystic ovarian syndrome women after treatment with laparoscopic ovarian drilling (LOD) versus gonadotropins. Int J Reprod Contracept Obstet Gynecol, 7(4) : 2320-1770.
Katsigianni M,Karageorgiou V,Lambrinoudaki I,Siristatidis C .2019 .Maternal polycystic ovarian syndrome in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatr, 24(12) : 1787-97.
Tan IF,Lim AJ,Indran IR,Kramer MS,Yong EL .2019 .Reproductive outcomes of women with polycystic ovarian syndrome following in-vitro fertilization - a meta-analysis and systematic review. Fertil Reprod, 01(4) : 193-201.
Estes JL,Pereira N,Lekovich J,Spandorfer SD .2016 .Perinatal outcomes of singletons following in vitro fertilization in women with polycystic ovarian syndrome [22G]. Obst Gyn, 0000483906(4) : 64S-5.
Chen YH,Wang Q,Zhang YN,Han X,Li DH,Zhang CL .2017 .Cumulative live birth and surplus embryo incidence after frozen-thaw cycles in PCOS: how many oocytes do we need?. J Assist Reprod Genet, 34(9) : 1153-9.
Moini A,Pirjani R,Rabiei M,Nurzadeh M,Sepidarkish M,Hosseini R .2019 .Can delivery mode influence future ovarian reserve? Anti-Mullerian hormone levels and antral follicle count following cesarean section: a prospective cohort study. J Ovarian Res, 12(1) : 1-7.
Hafizi L,Behrouznia A,Amirian M,Baradaran M,Pourhoseini SA .2020 .Evaluation of anti-mullerian hormone predictive value and antral follicle count in the success rate of ovarian drilling in polycystic ovary syndrome. Shiraz E Med, 21(6) : .
Chiofalo F,Ciuoli C,Formichi C,Selmi F,Forleo R,Neri O .2017 .Bariatric surgery reduces serum anti-mullerian hormone levels in obese women with and without polycystic ovarian syndrome. Obes Surg, 27(7) : 1750-4.
Köninger A,Kampmeier A,Mach P,Schmidt B,Strowitzki T,Kimmig R .2018 .Tight interplay in early pregnancy between follistatin and anti-mullerian hormone in women with polycystic ovarian syndrome (PCOS). Arch Gynecol Obstet, 297(5) : 1307-16.
Al-Gareeb AI,Abd Al-Amieer WS,Alkuraishy HM,Al-Mayahi TJ .2016 .Effect of body weight on serum homocysteine level in patients with polycystic ovarian syndrome: a case control study. Int J Reprod Biomed, 14(2) : 81.
Kim J,Mersereau JE,Khankari N,Bradshaw PT,McCullough LE,Cleveland R .2016 .Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case-control study. Cancer Cause Control, 27(3) : 403-14.
Pereira N,Lekovich J,Rosenwaks Z,Spandorfer SD .2015 .Do serum anti-Mullerian hormone levels correlate with pregnancy outcomes in patients with diminished ovarian reserve undergoing in vitro fertilization? Fertil Steril. , 07(3) : .
Simões-Pereira J,Nunes J,Aguiar A,Sousa S,Rodrigues C,Matias JS .2018 .Influence of body mass index in antiMüllerian hormone levels in 951 non-polycystic ovarian syndrome women followed at a reproductive medicine unit. Endocrine, 61(1) : 144-8.
Kocaay P,Siklar Z,Buyukfirat S,Berberoglu M. .2018 .The diagnostic value of anti-mullerian hormone in early post menarche adolescent girls with polycystic ovarian syndrome. J Pediatr Adol Gynec, 02(4) : 362-6.
Vagios S,Sacha CR,Hsu JY,Dimitriadis I,Bormann CL,James KE .2019 .Can anti-mullerian hormone (AMH) levels predict response to ovulation induction treatments in women with polycystic ovarian syndrome (PCOS)? Fertil Steril. , 07(3) : e391-2.
de Loos AD,Hund M,Buck K,Meun C,Sillman J,Laven JS .2019 .Establishing an anti-müllerian hormone (AMH) cut-off to determine polycystic ovarian morphology (PCOM) supporting diagnosis of polycystic ovarian syndrome (PCOS): the aphrodite study. Fertil Steril, 07(3) : .
Ishii R,Tachibana N,Okawa R,Enomoto M,Asami M,Toriumi R .2019 .Different anti-Mallerian hormone (AMH) levels respond to distinct ovarian stimulation methods in assisted reproductive technology (ART): clues to better ART outcomes. Reprod Med Biol, 18(3) : 263-72.
Cai WY,Gao JS,Luo X,Ma HL,Ge H,Liu N .2019 .Effects of metabolic abnormalities, hyperandrogenemia and clomiphene on liver function parameters among Chinese women with polycystic ovary syndrome: results from a randomized controlled trial. J Endocrinol Invest, 42(5) : 549-55.
Bedenk J,Vrtačnik-Bokal E,Virant-Klun I. .2020 .The role of antiMüllerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet, 37(1) : 89-100.
Detti L,Williams LJ,Osborne SE,Fletcher NM,Saed GM .2015 .LH-receptors and Inhibin-B production. Fertil Steril, 07(3) : .
Li G,Huang W,Zhang L,Tian Z,Zheng W,Wang T .2018 .A prospective cohort study of early-pregnancy risk factors for gestational diabetes in women with polycystic ovarian syndrome. Diabetes Metab Res, 34(5) : .
Cree-Green M,Cai N,Thurston JE,Coe GV,Newnes L,GarciaReyes Y .2018 .Using simple clinical measures to predict insulin resistance or hyperglycemia in girls with polycystic ovarian syndrome. Pediatr Diabetes, 19(8) : 1370-8.
Pergialiotis V,Trakakis E,Chrelias C,Papantoniou N,Hatziagelaki E. .2018 .The impact of mild hypercholesterolemia on glycemic and hormonal profiles, menstrual characteristics and the ovarian morphology of women with polycystic ovarian syndrome. -0002, 34(3) : 1-7.
Melado Vidales L,Fernández-Nistal A,Martínez Fernández V,Verdú Merino V,Bruna Catalán I .2017 .AntiMüllerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation. Minerva Ginecol, 69(3) : 03958-7.
0

Citations

0

Downloads

12

Views